Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

详细信息    查看全文

• 作者：J. Connor Wellsp>ap>p> ; p>p>bp> ; Igor Stukalinp>ap> ; Craig Nortonp>cp> ; Sandy Srinivasp>dp> ; Jae Lyun Leep>ep> ; Frede Donskovp>fp> ; Georg A. Bjarnasonp>gp> ; Haru Yamamotop>hp> ; Benoit Beuselinckp>ip> ; Brian I. Rinip>jp> ; Jennifer J. Knoxp>kp> ; Neeraj Agarwalp>lp> ; D. Scott Ernstp>mp> ; Sumanta K. Palp>np> ; Lori A. Woodp>op> ; Aristotelis Bamiasp>pp> ; Ajjai S. Alvap>qp> ; Ravindran Kanesvaranp>rp> ; Toni K. Choueirip>cp>p> ; p>p>&dagger ; p> ; Daniel Y.C. Hengp>ap>p> ; p>p>&dagger ; p>p> ; p>p>daniel.heng@albertahealthservices.cap>
• 关键词：Metastatic renal cell carcinoma ; Third line therapy ; Targeted therapy
• 刊名：European Urology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：71
• 期：2
• 页码：204-209
• 全文大小：639 K
• 卷排序：71

文摘

The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma (mRCC) is not well characterized and varies due to the lack of robust data to guide treatment decisions. This study examined the use of third-line therapy in a large international population.ObjectiveTo evaluate the use and efficacy of targeted therapy in a third-line setting.Design, setting, and participantsTwenty-five international cancer centers provided consecutive data on 4824 mRCC patients who were treated with an approved targeted therapy. One thousand and twelve patients (21%) received TTT and were included in the analysis.Outcome measurements and statistical analysisPatients were analyzed for overall survival (OS) and progression-free survival using Kaplan-Meier curves, and were evaluated for overall response. Cox regression analyses were used to determine the statistical association between OS and the six factors included in the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model. Subgroup analysis was performed on patients stratified by their IMDC prognostic risk status.Results and limitationsEverolimus was the most prevalent third-line therapy (27.5%), but sunitinib, sorafenib, pazopanib, temsirolimus, and axitinib were all utilized in over ≥9% of patients. Patients receiving any TTT had an OS of 12.4 mo, a progression-free survival of 3.9 mo, and 61.1% of patients experienced an overall response of stable disease or better. Patients not receiving TTT had an OS of 2.1 mo. Patients with favorable- (7.2%) or intermediate-risk (65.3%) disease had the highest OS with TTT, 29.9 mo and 15.5 mo, respectively, while poor-risk (27.5%) patients survived 5.5 mo. Results are limited by the retrospective nature of the study.ConclusionsTTT remains highly heterogeneous. The IMDC prognostic criteria can be used to stratify third-line patients. TTT use in favorable- and intermediate-risk patients was associated with the greatest OS.Patient summaryPatients with favorable- and intermediate-prognostic criteria disease treated with third-line targeted therapy have an associated longer overall survival compared with those with poor risk disease.